Drug
Jnj 90301900
Jnj 90301900: highest development phase Phase 3, developed by Johnson & Johnson. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| JNJ-90301900 (NBTXR3) NCT04892173 | Phase 3 | Carcinoma, Squamous Cell |
| JNJ-90301900 NCT06667908 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| JNJ-90301900 NCT07219212 | Phase 1 | Squamous Cell Carcinoma of Head and Neck |
Latest
No recent events.
Follow Jnj 90301900 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.